Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.

Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):847-56.

PMID:
22773800
2.

Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?

Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF.

Lung Cancer. 2005 Apr;48(1):93-102.

PMID:
15777975
3.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.

4.

[Treatment of the unresectable non small cell lung carcinoma].

Spásová I.

Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3. Review. Czech.

PMID:
16193938
5.

Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

Sacher AG, Le LW, Lau A, Earle CC, Leighl NB.

Cancer. 2015 Aug 1;121(15):2562-9. doi: 10.1002/cncr.29386. Epub 2015 Apr 17.

6.

National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China.

Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, Zhao H, Wu J, Zhang Y, Zhao L, Zhang J, Chen L, Zhang L.

Lung Cancer. 2012 Aug;77(2):371-5. doi: 10.1016/j.lungcan.2012.04.014. Epub 2012 May 10.

PMID:
22579298
7.

Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer.

Yu JL, Simmons C, Victor JC, Han D, Hogeveen S, Leighl N, Verma S.

Oncologist. 2011;16(9):1307-15. doi: 10.1634/theoncologist.2011-0079. Epub 2011 Aug 11.

8.

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel.

Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW.

Clin Transl Oncol. 2011 Jul;13(7):460-71. doi: 10.1007/s12094-011-0683-0.

PMID:
21775273
10.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
11.

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.

Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS, Lee JS.

Lung Cancer. 2012 Jun;76(3):387-92. doi: 10.1016/j.lungcan.2011.11.022. Epub 2011 Dec 18.

PMID:
22186628
12.

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.

Lung Cancer. 2009 Jun;64(3):319-25. doi: 10.1016/j.lungcan.2008.10.014. Epub 2008 Dec 17.

PMID:
19095327
13.

Metastatic non-small cell lung cancer in Brazil: treatment heterogeneity in routine clinical practice.

Naime FF, Younes RN, Kersten BG, Anelli A, Beato CA, Andrade RM, Carrara MP, Gross JL.

Clinics (Sao Paulo). 2007 Aug;62(4):397-404.

14.

Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis.

Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong YN, Benson AB 3rd, Shibata S, Schrag D.

J Natl Compr Canc Netw. 2009 Sep;7(8):895-904.

PMID:
19755049
15.

[Evidence-based practice guideline for unresectable advanced lung cancer in 2003].

Fukuoka M, Kurata T, Yamamoto N.

Nihon Geka Gakkai Zasshi. 2004 Jul;105(7):412-6. Review. Japanese.

PMID:
15303441
16.

Current and emerging therapies for patients with advanced non-small-cell lung cancer.

Sheth S.

Am J Health Syst Pharm. 2010 Jan 1;67(1 Suppl 1):S9-14. doi: 10.2146/ajhp090457. Review.

PMID:
20044378
18.

Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).

Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.

Anticancer Res. 2001 Mar-Apr;21(2B):1487-94.

PMID:
11396237
19.

Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.

Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G.

Lung Cancer. 2011 Jun;72(3):327-32. doi: 10.1016/j.lungcan.2010.09.012. Epub 2010 Nov 5.

PMID:
21056507

Supplemental Content

Support Center